drugset / Trial / NCT02072863
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of Phase 1b of the study is to determine the maximum tolerated dose (MTD) of oprozomib in combination with melphalan and prednisone (OMP). The purpose of Phase 2 of the study is to estimate the overall response rate (ORR) and complete response rate (CRR) of the OMP combination.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-01
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oprozomib | Small molecule | — | Oral |
| Background | Melphalan | Small molecule | 9 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | — |